Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

195.09 +3.89 (+2.03%)
Streaming Delayed Price Updated: 1:40 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
57 58 Next >
News headline image
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval ↗
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month. 
Via The Motley Fool
News headline image
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today ↗
The stock hasn't been a great investment in recent years, but there's hope for a brighter future. 
Via The Motley Fool
News headline image
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen ↗
 
Via Benzinga
News headline image
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich ↗
The fountain of youth might not be a myth in the future. 
Via The Motley Fool
News headline image
Elliott Wave Technical Analysis: Biogen Inc. ↗
We are looking for further downside into wave C which could take us back to the area of wave 4. 
Via Talk Markets
News headline image
1 Hot Growth Stock to Buy Now, and 1 to Avoid ↗
One company is gearing up for further growth while the other stumbles over itself. 
Via The Motley Fool
News headline image
1 Large-Cap Biotech Stock to Buy for 2023 and Beyond ↗
This company's best asset may be its pipeline. 
Via The Motley Fool
News headline image
Is Biogen's Stock Too Risky to Invest in? ↗
Even at a discount, investors may be taking on a big risk with Biogen. 
Via The Motley Fool
News headline image
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish ↗
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
News headline image
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval? ↗
There's more to the story with Biogen after receiving good news for Leqembi. 
Via The Motley Fool
News headline image
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill ↗
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read. 
Via Benzinga
News headline image
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug ↗
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.  
Via Benzinga
News headline image
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday ↗
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to 
Via Benzinga
News headline image
1 Green Flag and 1 Red Flag for Biogen ↗
Biogen beat the bear market this year. 
Via The Motley Fool
News headline image
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway ↗
 
Via Benzinga
News headline image
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock? ↗
Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock. 
Via InvestorPlace
News headline image
Top Picks For 2023: Anavex Life Sciences ↗
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett... 
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite? ↗
CMS already snubbed Biogen's first Alzheimer's drug. Will the second fare better? 
Via Investor's Business Daily
News headline image
1 Stock Defying the Downturn to Buy, and 1 to Avoid ↗
These two stocks might go in different directions in the future. 
Via The Motley Fool
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
Could Eli Lilly Stock Help You Become a Millionaire? ↗
Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%. 
Via The Motley Fool
News headline image
Biogen Names Priya Singhal as Executive Vice President, Head of Development
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
News headline image
What's Going On With Biogen Stock Today? ↗
Biogen Inc (NASDAQ: BIIB) shares traded higher Thursday morning before pulling back. Reports indicate that the FDA's process for approving Biogen's Alzheimer's drug Aduhelm was filled with... 
Via Benzinga
News headline image
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock ↗
Investors are closely watching two key spaces that could spark Lilly stock. 
Via Investor's Business Daily
News headline image
The Top Three Stocks Analysts Say To Buy
The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike. 
Via MarketBeat
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
News headline image
Roche's Follicular Lymphoma Therapy Scores FDA Approval ↗
 
Via Benzinga
News headline image
3 Nasdaq Stocks That Are Up 25% in 3 Months ↗
Should you jump on the bandwagon and buy these surging stocks? 
Via The Motley Fool
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.